Immunome
IMNM
153 hedge funds and large institutions have $1.07B invested in Immunome in 2025 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 64 increasing their positions, 38 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
68% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 38
45% more capital invested
Capital invested by funds: $739M → $1.07B (+$331M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13.7% more ownership
Funds ownership: 91.29% → 104.99% (+14%)
8% more funds holding
Funds holding: 142 → 153 (+11)
90% less call options, than puts
Call options by funds: $4.89M | Put options by funds: $50.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.5M |
| 2 |
Morgan Stanley
New York
|
+$14.2M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$10.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.37M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$7.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$10.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.02M |
| 3 |
JP Morgan Chase
New York
|
-$5.41M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.82M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.43M |
IMNM Hedge Fund Activity: Q3 2025 in Review
153 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2025, worth a combined $1.07B — up 45% from $739M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new IMNM positions and 15 closed out — a net gain of 12 holders — while 64 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $68.5M. The largest seller was Toronto Dominion Bank, cutting an estimated $10.4M.
- 153 institutional investors held Immunome (IMNM) as of Q3 2025, up from 142 in Q2 2025.
- Funds reported $1.07B of Immunome stock for Q3 2025, up 45% quarter-over-quarter.
- 27 funds opened new Immunome positions in Q3 2025 and 15 closed out, a net change of +12 holders.
- The largest Immunome buyer in Q3 2025 was Fidelity Investments, an estimated $68.5M added.
- The largest Immunome seller in Q3 2025 was Toronto Dominion Bank, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2025.